Ethos Laboratories Launches CNSDose Following MolDX Assessment
The diagnostic tool receives regulatory clearance to enter the U.S. market under exclusive distribution terms.
Ethos Laboratories has secured the exclusive right to distribute CNSDose in the United States following a successful MolDX® Technical Assessment.
The CNSDose platform represents a diagnostic offering positioned for the central nervous system market. The MolDX® Technical Assessment, conducted by the Centers for Medicare & Medicaid Services, validated the technical specifications and clinical utility of the product, clearing it for U.S. market entry.
The exclusive launch provides Ethos Laboratories with sole distribution rights in the American market. This arrangement follows a competitive technical review process that evaluated the product's performance standards and clinical applicability.
The timing positions Ethos Laboratories to capitalize on demand within the CNS diagnostic sector. Market adoption will depend on payer coverage decisions and clinical uptake among testing providers over the coming months.